64x Bio

0 Bewertungen

64x Bio is a biotechnology company dedicated to revolutionizing the manufacturing of cell and gene therapies by developing scalable solutions that enhance production efficiency and reduce costs. Their proprietary VectorSelect™ platform utilizes high-throughput genome engineering and screening technologies, combined with computational tools, to create optimized mammalian cell lines for viral vector production. This innovation addresses critical bottlenecks in the industry, enabling pharmaceutical and biotechnology companies to deliver advanced therapies to patients more effectively. Key Features and Functionality: - VectorSelect™ Platform: Employs novel high-throughput genome engineering and screening technologies to generate highly optimized mammalian cell lines, enhancing viral vector production efficiency. - AAV Apex Suite: A high-yield product line designed for adeno-associated virus (AAV) production, delivering titers exceeding E15 vg/L. This suite includes suspension-adapted HEK293 cell lines and optimized production processes, confirmed by partners across various serotypes and therapeutic payloads. - Machine Learning Integration: Utilizes computational tools to analyze extensive cell data, filtering trillions of genetic combinations to accelerate the discovery and optimization of high-yield cell lines. Primary Value and Solutions Provided: 64x Bio's technologies significantly reduce the cost and complexity of manufacturing viral vectors, a critical component in cell and gene therapies. By enhancing production efficiency, their solutions enable pharmaceutical and biotechnology companies to scale up manufacturing processes, meet growing demand, and bring life-saving therapies to market more rapidly. This advancement addresses one of the most pressing challenges in the field, facilitating broader access to innovative treatments for patients.